genomic and transcriptomic landscape of her2-low breast cancer
Published 1 year ago • 117 plays • Length 1:26Download video MP4
Download video MP3
Similar videos
-
1:45
the comprehensive genomic characterization of her2-low breast cancer
-
1:05
the genomic characterization of primary and metastatic her2-low breast cancers
-
1:56
clinical and genomic landscape of breast cancers carrying ccne1 amplification
-
1:49
early breast cancer: do we need chemotherapy in low genomic/high clinical risk (er /her2-)?
-
1:09
the exciting new field of her2-low breast cancer
-
0:32
highlights in her2-low breast cancer at sabcs 2022
-
2:02
her2-low breast cancer: the esmo expert consensus statements
-
0:30
the role of serds in the treatment landscape of patients with er /her2- breast cancer
-
5:37
therapeutic landscape for patients with her2-positive breast cancer with active brain metastases
-
3:10
genomic profiling of hr /her2- breast cancer and brain metastases
-
2:13
remaining questions surrounding her2-low breast cancer – how low can you go?
-
0:52
defining her2-low breast cancer as a clinical subtype
-
1:50
overview of recent changes to the treatment landscape for her2-positive crc
-
0:56
remaining questions on the management of her2-low breast cancer
-
1:17
clinical outcomes in women with metastatic her2-low breast cancer in the real world
-
0:35
key challenge associated with the management of hr /her2- breast cancer
-
1:20
future role of genomic tools in breast cancer treatment
-
1:33
questions remaining in the field of her2-low breast cancer
-
0:31
remaining questions regarding her2-low breast cancer